Loading
A phase 2 trial of FES PET in Breast cancer, run by University of Utah, recorded as terminated on the registry.
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma is a phase 2 interventional study registered as NCT04252859 by University of Utah, with 44 participants recorded, started 2020-12-11 and due to reach its primary completion in 2024-12-07. Interventions recorded: [18F]Fluoroestradiol (FES) PET/CT. Conditions recorded: Invasive Lobular Breast Carcinoma.
Linked to the technology FES PET because the registry's title names it ("18f fluoroestradiol pet") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
44 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2025-05-18), not from a publication
Source95% CI 21.67 to 46.82; Figures from the ClinicalTrials.gov results section (first posted 2025-05-18), not from a publication
SourceShares FES, FES PET (oestrogen receptor imaging), Breast cancer (all types) and the tag pipeline.
Shares FES, FES PET (oestrogen receptor imaging), Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares FES, Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.